Alvotech SA, a global biotech company specializing in biosimilar medicines, has announced the acquisition of Ivers-Lee Group, a family-owned company based in Burgdorf, Switzerland. This acquisition expands Alvotech's capacity in assembly and packaging, integrating Ivers-Lee's operations into its Technical Operations division. Peter Schüpbach, the managing director and grandson of Ivers-Lee's founder, will continue in his role and join Alvotech's senior leadership team. The acquisition supports Alvotech's plans for growth as it prepares to launch three new biosimilars in 2025. Ivers-Lee will remain a separate legal entity but will enhance Alvotech's ability to meet global demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.